EA201000545A1 - Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу - Google Patents

Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу

Info

Publication number
EA201000545A1
EA201000545A1 EA201000545A EA201000545A EA201000545A1 EA 201000545 A1 EA201000545 A1 EA 201000545A1 EA 201000545 A EA201000545 A EA 201000545A EA 201000545 A EA201000545 A EA 201000545A EA 201000545 A1 EA201000545 A1 EA 201000545A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pulsis
cybententan
mannite
microcrystal
composition
Prior art date
Application number
EA201000545A
Other languages
English (en)
Inventor
Джон Дейвид Блит
Эндрью Джон Дей
Киран Джеймс Леннон
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201000545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201000545A1 publication Critical patent/EA201000545A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описана фармацевтическая композиция, которая содержит-(3-метокси-5-метилпиразин-2-ил)-2-(4-[1,3,4-оксадиазол-2-ил]фенил)пиридин-3-сульфонамид с маннитом и/или микрокристаллической целлюлозой.
EA201000545A 2007-10-12 2008-10-09 Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу EA201000545A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15
PCT/GB2008/050928 WO2009047565A2 (en) 2007-10-12 2008-10-09 Composition 064

Publications (1)

Publication Number Publication Date
EA201000545A1 true EA201000545A1 (ru) 2010-10-29

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000545A EA201000545A1 (ru) 2007-10-12 2008-10-09 Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу

Country Status (35)

Country Link
US (2) US8168221B2 (ru)
EP (2) EP2209501B1 (ru)
JP (1) JP2011500548A (ru)
KR (1) KR20100099113A (ru)
CN (1) CN101896210A (ru)
AR (1) AR068845A1 (ru)
AT (1) ATE536893T1 (ru)
AU (1) AU2008309385B2 (ru)
BR (1) BRPI0818323A2 (ru)
CA (1) CA2701385A1 (ru)
CL (1) CL2008003022A1 (ru)
CO (1) CO6270344A2 (ru)
CR (1) CR11363A (ru)
CU (1) CU20100064A7 (ru)
CY (1) CY1112433T1 (ru)
DK (1) DK2209501T3 (ru)
DO (1) DOP2010000105A (ru)
EA (1) EA201000545A1 (ru)
ES (1) ES2377426T3 (ru)
HK (1) HK1143095A1 (ru)
HR (1) HRP20120085T1 (ru)
IL (1) IL204953A0 (ru)
MX (1) MX2010003989A (ru)
NI (1) NI201000052A (ru)
NZ (1) NZ585310A (ru)
PE (1) PE20091032A1 (ru)
PL (1) PL2209501T3 (ru)
PT (1) PT2209501E (ru)
SG (1) SG182138A1 (ru)
SI (1) SI2209501T1 (ru)
SV (1) SV2010003529A (ru)
TW (1) TW200924768A (ru)
UY (1) UY31385A1 (ru)
WO (1) WO2009047565A2 (ru)
ZA (1) ZA201002477B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
ES2377426T3 (es) 2007-10-12 2012-03-27 Astrazeneca Ab Composición de zibotentán que contiene manitol y celulosa microcristalina
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
US9492395B2 (en) * 2010-05-11 2016-11-15 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
MX369549B (es) * 2012-04-27 2019-11-12 Merck Patent Gmbh Un proceso para la fabricación de núcleos de tabletas duros con recubrimiento.
EP2872488B1 (en) 2012-07-16 2018-08-22 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3708154A1 (en) 2013-06-06 2020-09-16 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
WO2021200767A1 (ja) * 2020-03-31 2021-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤、医薬及びそれらの製造方法並びにキット

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (ru) 1995-06-07 2003-08-15 Зенека Лімітед Производные n-гетероарилпиридинсульфонамида, фармацевтическая композиция, способ получения и способ противодействия влияниям эндотелина
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
EE04156B1 (et) * 1997-04-28 2003-10-15 Texas Biotechnology Corporation Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
AU5248900A (en) * 1999-06-18 2001-01-09 Takeda Chemical Industries Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
RU2004114552A (ru) 2001-11-13 2005-02-20 Фармация Корпорейшн (Us) Пероральная дозированная форма сульфонамидного пролекарства
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
ES2377426T3 (es) 2007-10-12 2012-03-27 Astrazeneca Ab Composición de zibotentán que contiene manitol y celulosa microcristalina

Also Published As

Publication number Publication date
MX2010003989A (es) 2010-04-27
HK1143095A1 (en) 2010-12-24
US20120177705A1 (en) 2012-07-12
CO6270344A2 (es) 2011-04-20
NI201000052A (es) 2011-03-24
US20090099203A1 (en) 2009-04-16
TW200924768A (en) 2009-06-16
US8168221B2 (en) 2012-05-01
EP2209501B1 (en) 2011-12-14
KR20100099113A (ko) 2010-09-10
CN101896210A (zh) 2010-11-24
JP2011500548A (ja) 2011-01-06
EP2209501A2 (en) 2010-07-28
IL204953A0 (en) 2010-11-30
PL2209501T3 (pl) 2012-03-30
CR11363A (es) 2010-07-14
PE20091032A1 (es) 2009-08-15
NZ585310A (en) 2012-02-24
ATE536893T1 (de) 2011-12-15
DK2209501T3 (da) 2012-02-27
AU2008309385A1 (en) 2009-04-16
WO2009047565A3 (en) 2009-11-26
AU2008309385B2 (en) 2011-10-20
SV2010003529A (es) 2010-09-13
PT2209501E (pt) 2012-02-03
HRP20120085T1 (hr) 2012-02-29
BRPI0818323A2 (pt) 2017-05-16
SI2209501T1 (sl) 2012-03-30
EP2433620A1 (en) 2012-03-28
ZA201002477B (en) 2010-12-29
CU20100064A7 (es) 2011-10-05
DOP2010000105A (es) 2010-08-15
UY31385A1 (es) 2009-05-29
ES2377426T3 (es) 2012-03-27
CL2008003022A1 (es) 2010-07-23
CY1112433T1 (el) 2015-12-09
WO2009047565A2 (en) 2009-04-16
CA2701385A1 (en) 2009-04-16
SG182138A1 (en) 2012-07-30
AR068845A1 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
EA201000545A1 (ru) Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу
NO2018015I1 (no) 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid
CL2008002199A1 (es) Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
DK1874306T3 (da) Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
EA201070598A1 (ru) Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
DE102006051625A8 (de) Kombinationstherapie substituierter Oxazolidinone
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
CL2008002038A1 (es) Compuestos derivados de 3-fenil-1,2-oxazol, inhibidores de canales de sodio; y su uso para el tratamiento de un trastorno de dolor.
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
DK2035379T3 (da) Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
CL2012000326A1 (es) Compuestos derivados de heterociclos que presentan n como heteroátomo, n-[2-hidroxi-2-fenil-(4-oxadiazol o 4-tiadiazol)]etil sustituidos, agonistas del receptor de esfingosina-1-fosfato; composición farmacéutica; y su uso para tratar una enfermedad autoinmunitaria o inflamatoria crónica.
BRPI0514470B8 (pt) composto 5-[3-(4-benziloxifeniltio)-fur-2-il]-imidazolin-2,4-diona e composição farmacêutica
EA201070737A1 (ru) Терапевтическое применение соединений, обладающих аффинностью к переносчику серотонина, рецепторам серотонина и переносчику норадреналина
CL2008002058A1 (es) Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου